MEDICAL SERVICES

Departments

Languages

  • English

EDUCATION

Undergraduate Degree

  • Mount Holyoke College , 1979 , South Hadley , MA

Medical School

  • Yale University School of Medicine , 1983 , New Haven , CT

Internship

  • Yale-New Haven Hospital , 1984 , New Haven , CT

Residency

  • Massachusetts General Hospital , 1987 , Boston , MA

Fellowship

  • Massachusetts General Hospital , 1989 , Boston , MA

Philosophy of Care

I have been inspired by my patients and their families during my career. In particular, my research has focused on the effective care of children through characterization of direct or surrogate imaging markers to improve understanding of physiologic and metabolic profiles of pediatric brain tumors at diagnosis and after therapy.

During college, 2 medicine career exploration projects stimulated me to pursue medicine as my life work. A career in medicine includes my love of science and dedication to helping people. Patient care, teaching and research remain the hallmark of my career.

PROFESSIONAL HISTORY

Tina Young Poussaint, MD, FACR is Professor of Radiology at Harvard Medical School and is the Lionel W. Young Chair in Radiology at Boston Children’s Hospital where has served as an Attending Neuroradiologist. She received her Bachelor of Arts degree from Mount Holyoke College (magna cum laude) where she was elected to the Phi Beta Kappa Society. She received her MD with honors from Yale University School of Medicine where she was elected to the Alpha Omega Alpha Honor Medical Society. After an internship in pediatrics at Yale-New Haven Hospital (YNHH), she completed residency training in diagnostic radiology and a fellowship in neuroradiology at Massachusetts General Hospital (MGH). After serving on the neuroradiology faculty at MGH, and she then joined the faculty at Boston Children’s Hospital. Dr. Poussaint is board-certified in Diagnostic Radiology with a Certificate of Added Qualification in Neuroradiology.

Dr. Poussaint also serves as Director of Neuro-oncologic Imaging and as Director of the Pediatric Neuroradiology Fellowship. She is a Fellow of the American College of Radiology (ACR) and has served in several professional organizations including the ASNR, RSNA and SPR. She is a Past-President and Gold Medal Recipient of the American Society of Pediatric Neuroradiology (ASPNR). She is current President of the American Society of Neuroradiology. Dr. Poussaint is the Chair of the Institutional Review Board of Boston Children’s Hospital.

CERTIFICATIONS

  • American Board of Radiology, Diagnostic Radiology
  • American Board of Radiology, Neuroradiology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Machine Assist for Pediatric Posterior Fossa Tumor Diagnosis: A Multinational Study. Neurosurgery. 2021 Oct 13; 89(5):892-900. View abstract
  2. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2021 10 01; 23(10):1777-1788. View abstract
  3. Corrigendum to: Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors. Neuro Oncol. 2021 Sep 22. View abstract
  4. Deep Learning-Based Automatic Tumor Burden Assessment of Pediatric High-Grade Gliomas, Medulloblastomas, and Other Leptomeningeal Seeding Tumors. Neuro Oncol. 2021 Jun 26. View abstract
  5. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurol. 2021 05 01; 78(5):536-547. View abstract
  6. A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clin Cancer Res. 2021 May 01; 27(9):2442-2451. View abstract
  7. A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042). Pediatr Blood Cancer. 2021 04; 68(4):e28879. View abstract
  8. Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2020 11 26; 22(11):1696-1704. View abstract
  9. Deep Learning for Pediatric Posterior Fossa Tumor Detection and Classification: A Multi-Institutional Study. AJNR Am J Neuroradiol. 2020 09; 41(9):1718-1725. View abstract
  10. A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2020 06 09; 22(6):875-885. View abstract
  11. Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020 06; 21(6):e317-e329. View abstract
  12. MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma. AJNR Am J Neuroradiol. 2020 05; 41(5):874-881. View abstract
  13. Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. AJNR Am J Neuroradiol. 2020 04; 41(4):718-724. View abstract
  14. Brainstem Injury in Pediatric Patients Receiving Posterior Fossa Photon Radiation. Int J Radiat Oncol Biol Phys. 2019 12 01; 105(5):1034-1042. View abstract
  15. Primary Neoplasms of the Pediatric Brain. Radiol Clin North Am. 2019 Nov; 57(6):1163-1175. View abstract
  16. Lionel W. Young, MD. Radiology. 2019 Aug; 292(2):E3. View abstract
  17. Lionel W. Young, MD, FACR (1932-2019). Pediatr Radiol. 2019 Jun; 49(7):973-974. View abstract
  18. Indications and Imaging Modality of Choice in Pediatric Headache. Neuroimaging Clin N Am. 2019 May; 29(2):271-289. View abstract
  19. Quantifying radiation therapy response using apparent diffusion coefficient (ADC) parametric mapping of pediatric diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium. J Neurooncol. 2019 May; 143(1):79-86. View abstract
  20. Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network. J Nucl Med. 2019 05; 60(5):677-682. View abstract
  21. National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury. Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):152-168. View abstract
  22. Response to Harreld re: "Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee". Neuro Oncol. 2018 01 10; 20(1):144-145. View abstract
  23. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro Oncol. 2018 01 10; 20(1):13-23. View abstract
  24. Multiparametric Analysis of Permeability and ADC Histogram Metrics for Classification of Pediatric Brain Tumors by Tumor Grade. AJNR Am J Neuroradiol. 2018 Mar; 39(3):552-557. View abstract
  25. A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer. 2018 Feb; 65(2). View abstract
  26. Correlation of 18F-FDG PET and MRI Apparent Diffusion Coefficient Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2017 08; 58(8):1264-1269. View abstract
  27. Automated Processing of Dynamic Contrast-Enhanced MRI: Correlation of Advanced Pharmacokinetic Metrics with Tumor Grade in Pediatric Brain Tumors. AJNR Am J Neuroradiol. 2017 Jan; 38(1):170-175. View abstract
  28. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2016 09; 129(3):443-451. View abstract
  29. Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2016 05; 18(5):725-34. View abstract
  30. Introduction to 'Advances in Pediatric Neuroradiology'. Pediatr Radiol. 2015 Sep; 45 Suppl 3:S369. View abstract
  31. Pediatric brain tumors. Pediatr Radiol. 2015 Sep; 45 Suppl 3:S443-53. View abstract
  32. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst. 2015 Sep; 31(9):1433-45. View abstract
  33. Pediatric brain tumor consortium multisite assessment of apparent diffusion coefficient z-axis variation assessed with an ice-water phantom. Acad Radiol. 2015 Mar; 22(3):363-9. View abstract
  34. 18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium. J Nucl Med. 2014 Sep; 55(9):1473-80. View abstract
  35. Diversity in diagnostic radiology. Radiology. 2014 Jul; 272(1):301-2. View abstract
  36. Infantile postoperative encephalopathy: perioperative factors as a cause for concern. Pediatrics. 2014 Mar; 133(3):e751-7. View abstract
  37. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2014 Jan; 16(2):310-7. View abstract
  38. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology. 2013 Nov 19; 81(21 Suppl 1):S33-40. View abstract
  39. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer. 2013 Dec 01; 119(23):4180-7. View abstract
  40. Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2013 Aug; 54(8):1237-43. View abstract
  41. Pediatric brain tumors. Neuroimaging Clin N Am. 2013 Aug; 23(3):499-525. View abstract
  42. Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer. 2013 Sep; 60(9):1397-401. View abstract
  43. Callosal dysgenesis in fetuses with ventriculomegaly: levels of agreement between imaging modalities and postnatal outcome. Ultrasound Obstet Gynecol. 2012 Nov; 40(5):522-9. View abstract
  44. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J Neurooncol. 2012 Feb; 106(3):643-9. View abstract
  45. Imaging tumors of the pediatric central nervous system. Radiol Clin North Am. 2011 Jul; 49(4):589-616, v. View abstract
  46. Ultrasound and MRI of fetuses with ventriculomegaly: can cortical development be used to predict postnatal outcome? AJR Am J Roentgenol. 2011 Jun; 196(6):1457-67. View abstract
  47. Magnetic resonance volumetric assessments of brains in fetuses with ventriculomegaly correlated to outcomes. J Ultrasound Med. 2011 May; 30(5):595-603. View abstract
  48. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011 Mar; 13(3):298-306. View abstract
  49. MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro Oncol. 2011 Apr; 13(4):417-27. View abstract
  50. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2011 Mar; 13(3):290-7. View abstract
  51. Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2011 Feb; 52(2):188-95. View abstract
  52. Outcome of fetuses with cerebral ventriculomegaly and septum pellucidum leaflet abnormalities. AJR Am J Roentgenol. 2011 Jan; 196(1):W83-92. View abstract
  53. DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium. Childs Nerv Syst. 2011 Jan; 27(1):11-8. View abstract
  54. Frequency and cause of disagreements in imaging diagnosis in children with ventriculomegaly diagnosed prenatally. Ultrasound Obstet Gynecol. 2010 Nov; 36(5):582-95. View abstract
  55. Variability in PET quantitation within a multicenter consortium. Med Phys. 2010 Jul; 37(7):3660-6. View abstract
  56. Neurodevelopmental outcome of fetuses referred for ventriculomegaly. Ultrasound Obstet Gynecol. 2010 Apr; 35(4):405-16. View abstract
  57. Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. Am J Hematol. 2010 Feb; 85(2):135-7. View abstract
  58. Imaging of back pain in children. AJNR Am J Neuroradiol. 2010 May; 31(5):787-802. View abstract
  59. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer. 2009 Feb; 52(2):169-76. View abstract
  60. Meningioangiomatosis associated with meningioma: a case report. Acta Cytol. 2009 Jan-Feb; 53(1):93-7. View abstract
  61. Establishment and results of a magnetic resonance quality assurance program for the pediatric brain tumor consortium. Acad Radiol. 2008 Sep; 15(9):1099-110. View abstract
  62. Frequency and cause of disagreements in diagnoses for fetuses referred for ventriculomegaly. Radiology. 2008 May; 247(2):516-27. View abstract
  63. Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC). Eur J Nucl Med Mol Imaging. 2008 Sep; 35(9):1651-8. View abstract
  64. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol. 2008 Jun; 10(3):341-7. View abstract
  65. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol. 2008 Feb 20; 26(6):919-24. View abstract
  66. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res. 2008 Feb 15; 14(4):1124-30. View abstract
  67. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6712-8. View abstract
  68. The Neuroimaging Center of the Pediatric Brain Tumor Consortium-collaborative neuroimaging in pediatric brain tumor research: a work in progress. AJNR Am J Neuroradiol. 2007 Apr; 28(4):603-7. View abstract
  69. Changes in cerebral cortex of children treated for medulloblastoma. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):992-8. View abstract
  70. Predicting survival of children with CNS tumors using proton magnetic resonance spectroscopic imaging biomarkers. Int J Oncol. 2007 Mar; 30(3):651-7. View abstract
  71. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007 Apr; 9(2):145-60. View abstract
  72. Neuroimaging of the child with developmental delay. Top Magn Reson Imaging. 2007 Feb; 18(1):75-92. View abstract
  73. Evaluation of real-time single-shot fast spin-echo MRI for visualization of the fetal midline corpus callosum and secondary palate. AJR Am J Roentgenol. 2006 Dec; 187(6):1505-11. View abstract
  74. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer. 2006 Nov 01; 107(9):2291-7. View abstract
  75. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol. 2007 Mar; 82(1):95-101. View abstract
  76. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res. 2006 Mar 01; 12(5):1540-6. View abstract
  77. Advanced neuroimaging of pediatric brain tumors: MR diffusion, MR perfusion, and MR spectroscopy. Neuroimaging Clin N Am. 2006 Feb; 16(1):169-92, ix. View abstract
  78. X-linked creatine transporter defect: a report on two unrelated boys with a severe clinical phenotype. J Inherit Metab Dis. 2006 Feb; 29(1):214-9. View abstract
  79. Age associated increase in the prevalence of chromosome 22q loss of heterozygosity in histological subsets of benign meningioma. J Med Genet. 2006 Mar; 43(3):285-7. View abstract
  80. Diencephalic syndrome: a cause of failure to thrive and a model of partial growth hormone resistance. Pediatrics. 2005 Jun; 115(6):e742-8. View abstract
  81. Superficial neurofibroma: a lesion with unique MRI characteristics in patients with neurofibromatosis type 1. AJR Am J Roentgenol. 2005 Mar; 184(3):962-8. View abstract
  82. MR imaging of abdominopelvic involvement in neurofibromatosis type 1: a review of 43 patients. Pediatr Radiol. 2005 Mar; 35(3):317-22. View abstract
  83. Perfusion MRI of U87 brain tumors in a mouse model. Magn Reson Med. 2004 May; 51(5):893-9. View abstract
  84. Neuroimaging findings in neurofibromatosis type 1 and 2. Neuroimaging Clin N Am. 2004 May; 14(2):149-70, vii. View abstract
  85. Spectroscopic and perfusion magnetic resonance imaging predictors of progression in pediatric brain tumors. Cancer. 2004 Mar 15; 100(6):1246-56. View abstract
  86. MRI and 1H MRS findings in Smith-Lemli-Opitz syndrome. Neuroradiology. 2004 Jan; 46(1):3-14. View abstract
  87. Chemotherapy for progressive low-grade gliomas in children older than ten years: the Dana-Farber experience. Pediatr Hematol Oncol. 2003 Oct-Nov; 20(7):497-504. View abstract
  88. Scoliosis: evidence-based diagnostic evaluation. Neuroimaging Clin N Am. 2003 May; 13(2):335-41, xii. View abstract
  89. Interobserver reproducibility of volumetric MR imaging measurements of plexiform neurofibromas. AJR Am J Roentgenol. 2003 Feb; 180(2):419-23. View abstract
  90. Prediction of adverse outcome with cerebral lactate level and apparent diffusion coefficient in infants with perinatal asphyxia. Radiology. 2002 Dec; 225(3):859-70. View abstract
  91. Imaging of pediatric head trauma. Neuroimaging Clin N Am. 2002 May; 12(2):271-94, ix. View abstract
  92. Magnetic resonance of metabolic and degenerative diseases in children. Top Magn Reson Imaging. 2002 Feb; 13(1):3-21. View abstract
  93. Pediatric Head Trauma. Neuroimaging Clin No Am. 2002; In Press. View abstract
  94. MR of Metabolic and Degenerative Disease in Childhood. Topics in MRI. 2002. View abstract
  95. Thallium-201 single-photon emission CT in recurrent squamous cell carcinoma of the head and neck. AJNR Am J Neuroradiol. 2002 Jan; 23(1):174-5. View abstract
  96. Magnetic resonance imaging of pediatric brain tumors: state of the art. Top Magn Reson Imaging. 2001 Dec; 12(6):411-33. View abstract
  97. Magnetic resonance imaging (MRI) is one of the most important imaging modalities in pediatric neuroradiology. Top Magn Reson Imaging. 2001 Dec; 12(6):359. View abstract
  98. Editorial. Topics in MRI. 2001; 359. View abstract
  99. MR Imaging of Pediatric Brain Tumors: State of the Art. Topics in MRI. 2001; 12: 411-433. View abstract
  100. Thallum-201 Single-Proton Emission CT versus CT for the Detection of Recurrent Squamous Cell Carcinoma of the Head and Neck. AJNR Am J Neuroradiol. 2001; 22(1). View abstract
  101. Congenital Malformations of the Cerebellum and Posterior Fossa: Radiographic Diagnosis and Surgical Treatment. . The Cerebellum and Its Disorders. 2001. View abstract
  102. Imaging of the Developmentally Delayed Child. Magnetic Resonance Imaging Clinics of North America. 2001; 999-119. View abstract
  103. Magnetic resonance spectroscopy and magnetic resonance imaging findings in Krabbe's disease. J Child Neurol. 2001 Jul; 16(7):522-6. View abstract
  104. Proton magnetic spectroscopic imaging of the child's brain: the response of tumors to treatment. Neuroradiology. 2001 Feb; 43(2):169-77. View abstract
  105. Periventricular nodular heterotopia in patients with filamin-1 gene mutations: neuroimaging findings. Pediatr Radiol. 2000 Nov; 30(11):748-55. View abstract
  106. Case Report: Supratentorial intraventricular PNET. ACR Learning File CD-ROM Series. 2000. View abstract
  107. Case Report: Supratentorial ependymoma. ACR Learning File CD-ROM Series. 2000. View abstract
  108. Role of intraoperative skeletal scintigraphy in the localization of osteoblastomas. Clin Nucl Med. 2000 Oct; 25(10):819-20. View abstract
  109. Neurological dysfunction associated with postoperative cerebellar mutism. J Neurooncol. 2000 May; 48(1):75-81. View abstract
  110. Neuroradiology portion of Pediatric Radiology Chapter . Mosby Yearbook. 1999. View abstract
  111. Cervicomedullary astrocytomas of childhood: clinical and imaging follow-up. Pediatr Radiol. 1999 Sep; 29(9):662-8. View abstract
  112. Occult lumbosacral dysraphism in children and young adults: diagnostic performance of fast screening and conventional MR imaging. Radiology. 1999 Jun; 211(3):767-71. View abstract
  113. Structural anomalies revealed by neuroimaging studies in the brains of patients with neurofibromatosis type 1 and large deletions. Genet Med. 1999 May-Jun; 1(4):136-40. View abstract
  114. Imaging of neuroendocrine disorders of childhood. Neuroimaging Clin N Am. 1999 Feb; 9(1):157-75. View abstract
  115. Neuroimaging of scoliosis in childhood. Neuroimaging Clin N Am. 1999 Feb; 9(1):195-221. View abstract
  116. Scoliosis circa 2000: radiologic imaging perspective. II. Treatment and follow-up. Skeletal Radiol. 1998 Dec; 27(12):651-6. View abstract
  117. Scoliosis circa 2000: radiologic imaging perspective. I. Diagnosis and pretreatment evaluation. Skeletal Radiol. 1998 Nov; 27(11):591-605. View abstract
  118. Childhood brain tumor: neuroimaging correlated with disease outcome. Pediatr Neurol. 1998 Oct; 19(4):259-62. View abstract
  119. Focal cortical dysplasia with glioproliferative changes causing seizures: report of 3 cases. Pediatr Neurosurg. 1998 May; 28(5):261-6. View abstract
  120. Tectal tumors of childhood: clinical and imaging follow-up. AJNR Am J Neuroradiol. 1998 May; 19(5):977-83. View abstract
  121. Efficacy of fast screening MR in children and adolescents with suspected intracranial tumors. AJNR Am J Neuroradiol. 1998 Mar; 19(3):529-34. View abstract
  122. Diencephalic syndrome: clinical features and imaging findings. AJNR Am J Neuroradiol. 1997 Sep; 18(8):1499-505. View abstract
  123. Angiographic changes after pial synangiosis in childhood moyamoya disease. AJNR Am J Neuroradiol. 1997 May; 18(5):837-45. View abstract
  124. Imaging of the spine and spinal cord. Practical pediatric imaging. Diagnostic radiology of infants and children. 1997; 259-325.. View abstract
  125. Structural imaging of CNS tumors. Cancer of the nervous system. 1997; 54-97. View abstract
  126. Hemorrhagic pituitary adenomas of adolescence. AJNR Am J Neuroradiol. 1996 Nov-Dec; 17(10):1907-12. View abstract
  127. Maternal phenylketonuria: magnetic resonance imaging of the brain in offspring. J Pediatr. 1996 Jun; 128(6):770-5. View abstract
  128. Structural abnormalities in brain magnetic resonance images of depressed children. J Am Acad Child Adolesc Psychiatry. 1996 Mar; 35(3):307-11. View abstract
  129. Pediatric orbital and visual pathway lesions. Neuroimaging Clin N Am. 1996 Feb; 6(1):179-98. View abstract
  130. Hemorrhagic vasculopathy after treatment of central nervous system neoplasia in childhood: diagnosis and follow-up. AJNR Am J Neuroradiol. 1995 Apr; 16(4):693-9. View abstract
  131. Brain abscesses caused by Clostridium septicum as a complication of hemolytic-uremic syndrome. Pediatr Infect Dis J. 1995 Jan; 14(1):72-4. View abstract
  132. MRI abnormalities in major psychiatric disorders: an exploratory comparative study. J Neuropsychiatry Clin Neurosci. 1995; 7(1):49-53. View abstract
  133. Imaging of the pediatric spine and spinal neuraxis. Spine: state of the art reviews. Spinal imaging. 1995; 73-92. View abstract
  134. Dysraphic myelodysplasias associated with urogenital and anorectal anomalies: prevalence and types seen with MR imaging. AJR Am J Roentgenol. 1994 Nov; 163(5):1199-203. View abstract
  135. Imaging of pediatric central nervous system infections. Neuroimaging Clin N Am. 1994 May; 4(2):367-91. View abstract
  136. Imaging of pediatric CNS infections. Neuroimaging Clin No Am. 1994; 4:367-91. View abstract
  137. MR quantification of cerebral ventricular volume using a semiautomated algorithm. AJNR Am J Neuroradiol. 1993 Nov-Dec; 14(6):1373-8. View abstract
  138. Anterior communicating artery collateral flow protection against ischemic change during carotid endarterectomy. J Neurosurg. 1993 Sep; 79(3):379-82. View abstract
  139. Cystic retrocerebellar malformations: unification of the Dandy-Walker complex and the Blake's pouch cyst. Pediatr Radiol. 1993; 23(4):258-60. View abstract
  140. MR and CT imaging in multiple sclerosis. Current practice in radiology. 1993; 502-511. View abstract
  141. Magnetic resonance imaging of spine.[Book Review]. Year Book Med Pub. 1991; 75:666. View abstract
  142. Ferromagnetism and MR imaging: safety of carotid vascular clamps. AJNR Am J Neuroradiol. 1990 Mar-Apr; 11(2):267-72. View abstract
  143. Modified schema for classifying positive-pressure tympanograms. Pediatrics. 1982 Mar; 69(3):351-4. View abstract
  144. Malignant melanoma in renal-transplant recipients. Lancet. 1981 May 30; 1(8231):1196-9. View abstract
  145. Polyethylene glycol in suppositories: carcinogenic? Ann Intern Med. 1980 Nov; 93(5):781. View abstract
  146. Choline to N-Acetylaspartate Ratio is Predictive of Pediatric BrainTumor Progression . View abstract
  147. Neuroimaging of Pediatric Brain Tumors: Gd-DTPA Enhanced, Hemodynamic and Diffusion MR Imaging Compared to MR Spectroscopic Imaging. . AJNR, In Press. View abstract
  148. MRSI of Antiangiogenesis/Radiation in Pediatric Gliomas . View abstract
  149. Predicting Clinical Outcome in Perinatal Asphyxia by MRI and MRS. View abstract
  150. Rasmussen Encephalitis: typical and atypical MRI findings with pathologic correlation. View abstract
  151. Predicting Clinical Outcome in Infants with Perinatal Asphyxia. View abstract
  152. Predicting Clinical Outcome in Perinatal Asphyxia by MRI and MRS. View abstract
  153. Predicting Clinical Outcome in Infants with Perinatal Asphyxia. View abstract
  154. Comparison of in Vivo proton MRS of pediatric brain tumors with ex vivo Magic Angle Spinning MRS of intact biopsy tumor samples . View abstract
  155. MRSI of Antiangiogenesis/Radiation in Pediatric Gliomas. View abstract
  156. Rasmussen Encephalitis: typical and atypical MRI findings with pathologic correlation. View abstract
  157. MR Imaging and MR Spectroscopy Findings in Smith-Lemli-Opitz Syndrome. View abstract
  158. MR Imaging and MR Spectroscopy Findings in Smith-Lemli-Opitz Syndrome. View abstract
  159. Choline to N-Acetylaspartate Ratio is Predictive of Pediatric Brain Tumor Progression. View abstract
  160. Comparison of in Vivo proton MRS of pediatric brain tumors with ex vivo Magic Angle Spinning MRS of intact biopsy tumor samples . View abstract